Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease
- Conditions
- Graft-versus-Host Disease
- Registration Number
- NCT00054613
- Lead Sponsor
- Mallinckrodt
- Brief Summary
The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).
- Detailed Description
For patients who survive allogeneic bone marrow transplants greater than 100 days, chronic GvHD is a major cause of non-relapse morbidity and mortality. Depending on the presence of known associated risk factors, chronic GvHD will occur in 20-50% of these transplant recipients, with mortality rates varying from 20 to 70%.
Because a lymphocyte-mediated immune reaction is thought to be involved in GvHD, suppression of these cells by means other than medications could have benefit in the GvHD population.
ECP is a technique in which peripheral white blood cells are exposed to a photoactivatable compound (UVADEX) administered extracorporeally and ultraviolet A light. After cells are reinfused into the patient, their function is altered, thereby activating mechanisms that allow for further regulation of specific lymphocyte populations.
The purpose of this study is to determine whether ECP, in conjunction with standard therapy, is effective in the treatment of chronic GvHD. Efficacy of the therapy with respect to skin manifestations of the disease will be determined by a blinded skin assessor.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
- Documented skin disease classical for chronic GvHD (e.g. hypopigmentation, hyperpigmentation, lichenoid lesions, sclerodermatous lesions)greater than or equal to 100 days post transplantation.
- Patients with documented chronic GvHD that is corticosteroid refractory, corticosteroid dependent or corticosteroid intolerant.
- Women of childbearing potential must agree to use a reliable method of birth control for the duration of this study.
- Patients must weight at least 40 kg (88 lbs.)
- Active gastrointestinal bleeding
- Previous treatment with ECP
- Females who are pregnant and/or lactating
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (31)
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
University of Florida
🇺🇸Gainesville, Florida, United States
Rush Presbyterian - St. Lukes Medical Center
🇺🇸Chicago, Illinois, United States
University of Chicago
🇺🇸Chicago, Illinois, United States
Tufts New England Medical Center
🇺🇸Boston, Massachusetts, United States
Brigham and Womens
🇺🇸Boston, Massachusetts, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Kansas City Cancer Center
🇺🇸Kansas City, Missouri, United States
University of Nebraska
🇺🇸Omaha, Nebraska, United States
Jewish Hospital
🇺🇸Cincinnati, Ohio, United States
Scroll for more (21 remaining)University of Arkansas for Medical Sciences🇺🇸Little Rock, Arkansas, United States